Sequenom has appointed Myla Lai-Goldman to its board of directors and to the board's science committee. Lai-Goldman is a managing partner at Personalized Science and CEO of GeneCentric Diagnostics. Previously, she served as executive vice president, chief medical officer, and chief scientific officer at Laboratory Corporation of America. <\/p>\n
Aushon BioSystems has appointed Martin Verhoef to be company CEO and to serve on its board of directors. Verhoef takes over the position from company Founder Peter Honkanen, who will assume the post of COO and will continue as a board director. <\/p>\n
Verhoef has spent 25 years in the life science research tools and molecular diagnostics business. He formerly was CEO at MiraDx and PrimeraDx, he led Ciphergen's Biosystems Division, and he held senior management jobs at Agilent in Germany and in the US. <\/p>\n
The New York Genome Center has appointed Dirk Evers and Kevin Shianna to its leadership team. Evers, who will serve as senior vice president of bioinformatics, joins NYGC from Illumina, where he led the company's computational biology efforts in the UK. Previously, he served as managing director of the International Graduate School in Bioinformatics and Genome Research at the Center for Biotechnology at Bielefeld University. Shianna will serve as senior vice president of sequencing operations at the NYGC. He joins from Duke University, where he was an assistant professor in the School of Medicine, director of operations for the Center for Human Genome Variation, and founding director for the Genomic Analysis Facility. <\/p>\n<\/p>\n
Read more here: Sequenom has appointed Myla Lai-Goldman to its board of directors and to the board's science committee. Continue reading
\nLBNL Seeks Licensees for Highly Specific and Sensitive DNA Extraction Method<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"